CN93 - Strategic patient collaboration, cancer theme Karolinska comprehensive cancer center (CCC)

Background

The “2.0 strategy for patient involvement" aims to involve patients and relatives to become active partners at Karolinska CCC. The strategy is based on involvement on different levels; strategic, operational, individual and in specific projects Involvement of patients and relatives is essential for better research and healthcare. In the strategic patient council, two patient representatives meets with medical and nursing managers regularly. The patient representatives address strategic topics to the council and the aim is also to exchange information about ongoing projects. The Strategic Council maps the level of existing patient involvement at operational level. The mapping resulted in a GAP analysis to identify areas of improvement in relation to the OECI standards for patient involvement.

Methods

The working method for GAP analysis has been questionnaires and focus groups based on areas selected by the authors according to OECI standards. Informants have been expert groups/professionals/managers.

Results

Patient Involvement organization. Strategic level: The representatives from the Patient and Relatives Council meets with the management team 4 times a year. Term of office 3-4 years (overlapping). Examples from the agenda; Relevant outcome data to be published, governance and organizational development, continuity of care, access to care. The aim of this collaboration is to involve patients in the development of cancer care at a strategic level. This grouping has an advisory function and reports to the management of the Cancer Theme. Operational level: Collaboration with patient representatives on processes that are important for the outcome of care in the patient flow. 2 Representatives. Term of office – 3-4 years (overlapping). Joint evaluation of collaboration.

Conclusions

Patient representatives’ views on patient involvement 2.0; “We observe that Theme Cancer has taken note of this and developed Patient Involvement 2.0 and initiated the implementation. In our role as patient representatives, we have seen the difference patient involvement makes. We can use the experiences of those affected and close relations to make a difference, and that encourages us to continue”.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.